Literature DB >> 8383753

Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin.

M Manning1, W H Sawyer.   

Abstract

Selective agonists and antagonists are powerful tools for studies on AVP and OT receptors and on the physiological and pathophysiological roles of AVP and OT. Here we show how some of these peptides and their radiolabelled derivatives were designed. We also present examples of the currently available cyclic and linear OT and AVP agonists and antagonists from our laboratories.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8383753     DOI： 10.3109/10799899309073655

Source DB:  PubMed          Journal:  J Recept Res        ISSN： 0197-5110


  10 in total

1.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 3.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

Review 4.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Oxytocin and its receptors are synthesized in the rat vasculature.

Authors:  M Jankowski; D Wang; F Hajjar; S Mukaddam-Daher; S M McCann; J Gutkowska
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 7.  Vasopressin: behavioral roles of an "original" neuropeptide.

Authors:  Heather K Caldwell; Heon-Jin Lee; Abbe H Macbeth; W Scott Young
Journal:  Prog Neurobiol       Date:  2007-11-04       Impact factor: 11.685

Review 8.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

9.  Development of a human vasopressin V1a-receptor antagonist from an evolutionary-related insect neuropeptide.

Authors:  Maria Giulia Di Giglio; Markus Muttenthaler; Kasper Harpsøe; Zita Liutkeviciute; Peter Keov; Thomas Eder; Thomas Rattei; Sarah Arrowsmith; Susan Wray; Ales Marek; Tomas Elbert; Paul F Alewood; David E Gloriam; Christian W Gruber
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

10.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

Authors:  B Chini; B Mouillac; Y Ala; M N Balestre; S Trumpp-Kallmeyer; J Hoflack; J Elands; M Hibert; M Manning; S Jard
Journal:  EMBO J       Date:  1995-05-15       Impact factor: 11.598
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.